New: our quarterly report on the S&P 500, read from 500 companies’ own filings and calls. Read the Q3 2026 report

CASI Pharmaceuticals Inc. (CASIF) vs Passage Bio, Inc. (PASG)

CASI Pharmaceuticals Inc. and Passage Bio, Inc. are both Biotechnology companies. CASI Pharmaceuticals Inc. and Passage Bio, Inc. are of similar size ($12.4M and $11.6M). Across the 8 metrics below, Passage Bio, Inc. leads on 5 and CASI Pharmaceuticals Inc. on 3.

Valuation

Metric CASIF PASG Biotechnology median
P/E n/m n/m 8.49
P/S 0.10 — 8.56
P/B n/m 253.58 2.04
Price to free cash flow n/m n/m 23.84
EV/EBITDA n/m 0.21 0.69
EV/Sales 0.87 — 8.00
Earnings yield (2,455.91%) (262.60%) (35.81%)
Free cash flow yield (3,455.46%) (257.29%) (25.41%)

Profitability

Metric CASIF PASG Biotechnology median
Gross margin 48.65% — 70.18%
Operating margin (206.87%) — 0.00%
Net margin (232.03%) — 0.00%
Free cash flow margin — — 0.00%
Return on equity 271.28% (212.27%) (51.58%)
Return on assets (121.17%) (69.68%) (45.91%)
Return on invested capital 0.00% 0.00% 0.00%

Growth

Metric CASIF PASG Biotechnology median
Revenue growth (TTM) (27.42%) — 7.20%
EPS growth (last fiscal year) (1.17%) 32.94% 29.04%
Revenue growth, 5-year CAGR 6.47% — 9.54%
Net income growth, 5-year CAGR — — 0.00%

Health

Metric CASIF PASG Biotechnology median
Debt to equity (0.34) 0.00 0.00
Current ratio 0.15 1.00 4.79
Net debt to EBITDA (0.43) 0.96 1.01

Dividend

Metric CASIF PASG Biotechnology median
Dividend yield — — 0.41%
Payout ratio — — —

Size

Metric CASIF PASG Biotechnology median
Market cap 12.39m 11.62m 150.57m

Compare with another peer

Any metric, up to five companies and an Excel export Powerpack